These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

849 related items for PubMed ID: 26768240

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.
    Cardiovasc Diabetol; 2017 Mar 01; 16(1):31. PubMed ID: 28249585
    [Abstract] [Full Text] [Related]

  • 3. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I, Schweizer A, Dejager S.
    Hosp Pract (1995); 2011 Feb 01; 39(1):7-21. PubMed ID: 21441754
    [Abstract] [Full Text] [Related]

  • 4. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
    Jermendy G.
    Orv Hetil; 2016 Apr 17; 157(16):603-10. PubMed ID: 27063427
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May 17; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J, Sands M, Burciu C, Reaven P.
    Diab Vasc Dis Res; 2015 May 17; 12(3):154-63. PubMed ID: 25852133
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 17; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS.
    Cleve Clin J Med; 2009 Dec 17; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 17; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 13. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R.
    Adv Ther; 2015 Nov 17; 32(11):1065-84. PubMed ID: 26578430
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
    Mora PF, Johnson EL.
    Endocr Pract; 2017 Jan 17; 23(1):89-99. PubMed ID: 27819769
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA, Marx N, Federici M.
    Nutr Metab Cardiovasc Dis; 2015 Aug 17; 25(8):697-705. PubMed ID: 26164634
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.